Beam Therapeutics (BEAM) Capital Expenditures (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Capital Expenditures data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 27.18% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $438000.0, a 70.02% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 52.4% from the prior year.
• Capital Expenditures for Q1 2026 stood at $2.2 million, up from -$1.9 million in the prior quarter.
• Over the last five years, Capital Expenditures for BEAM reached as high as $31.8 million in Q3 2022 and fell as low as -$28.7 million in Q4 2023.
• Historically, Capital Expenditures has averaged $3.2 million across 5 years, with a median of $2.4 million in 2024.
• Across the five-year window, Capital Expenditures soared 8173.51% in 2022 and slumped 584.33% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $8.3 million in 2022, then slumped by 447.9% to -$28.7 million in 2023, then jumped by 101.33% to $383000.0 in 2024, then slumped by 584.33% to -$1.9 million in 2025, then jumped by 220.32% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $2.2 million in Q1 2026, -$1.9 million in Q4 2025, and -$3.1 million in Q3 2025.